Many cancers remain difficult to treat because the therapies currently available, even the most recent ones such as immunotherapies, are not sufficiently effective in the long term. Developing innovative, personalized and sustainable therapies is a major challenge for researchers and physicians.
At the forefront of cancer immunotherapy and with international expertise in epigenetics, the Institut Curie teams have mobilized around an ambitious project: EpCART. They are conducting the project in partnership with Mnemo Therapeutics and the MEARY cell and gene therapy center of the AP-HP.
The project aims to test an innovative and personalized therapeutic approach combining immuno-epigenetics with CAR-T therapies, which was born out of research conducted at the Institut Curie and developed by its spin-off Mnemo Therapeutics. After full preclinical validation of this unique approach, a clinical trial will evaluate the feasibility of producing these original cell therapies and the absence of side effects in patients with solid tumors.
